Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

This trial is testing whether combining nab-sirolimus (a targeted mTOR inhibitor) with hormone therapy can help control low-grade serous ovarian cancer that has come back after prior treatment. **You may be eligible if...** - You have been diagnosed with low-grade serous ovarian cancer that has come back - Your cancer is measurable on imaging - You are in good physical condition (ECOG 0–1) - At least 4 weeks have passed since your last major surgery and at least 2 weeks since any radiation - Your blood counts and organ function meet minimum requirements **You may NOT be eligible if...** - You have uncontrolled brain metastases - You have severe liver, kidney, or bone marrow problems - You are pregnant or breastfeeding - You have significant uncontrolled infections Talk to your doctor to see if this trial is right for you.